Author

G. M. Arndt

Listed by name: these papers carry no ORCID for this author, so different people with the same name may be mixed together.

Biology Disciplines

Click to filter author papers

Cancer Biology· 1 Pharmacology & Toxicology· 1

Signature Assays, Organisms & Methods

Click to filter · or open tag

Assay:bulk RNA-seq· 1 Research Focus:cell type annotation· 1 Approach:deep learning· 1 Research Focus:drug response / drug discovery· 1 Approach:experimental assay· 1 Organism:human· 1 Organism:mouse· 1 Approach:statistical model· 1

Frequent Co-Authors

A. J. Mead· 1 shared A. Rodriguez-Meira· 1 shared A. Schnegg-Kaufmann· 1 shared A. Unnikrishnan· 1 shared B. Mouysset· 1 shared C. Colin· 1 shared C. J. Jolly· 1 shared D. Braguer· 1 shared

Activity by Year

2022-2022 · peak 2/yr

Co-Author Collaboration Network

10 top collaborators · 21 mutual co-author links

Click any collaborator node to inspect or filter shared papers

Focal author (center)Selected co-authorORCID co-authorUnlinked name

Curved chords = mutual co-authorship

1 shared paperCancer Biology

A. J. Mead

Mutual co-authors in cluster

Author profile →

2 papers

Recent·Most cited

Combination drug screen targeting glioblastoma core vulnerabilities reveals pharmacological synergisms

J. Ariey-Bonnet, R. Berges, M.-P. Montero, B. Mouysset, P. Piris, K. Muller, G. Pinna, T. W. Failes, G. M. Arndt, N. Baeza-Kallee, C. Colin, O. Chinot, D. Braguer, X. Morelli, N. ANDRE, , E. Pasquier

This study identifies synergistic drug combinations for glioblastoma by screening core vulnerabilities and validating them in preclinical models.

bioRxiv · Dec 14, 2022Pharmacology & Toxicology

Single cell genotyping of matched bone marrow and peripheral blood cells in treatment naive and AZA-treated MDS and CMML

A. Schnegg-Kaufmann, J. A. I. Thoms, G. S. Bhuyan, H. R. Hampton, L. Vaughan, K. Rutherford, P. M. Kakadia, E. M. V. Johansson, T. Failes, G. M. Arndt, J. Koval, R. Lindeman, P. Warbuton, A. Rodriguez-Meira, A. J. Mead, , J. E. Pimanda

This study examines the contribution of mutated hematopoietic stem and progenitor cells to blood cell populations in MDS and CMML before and after AZA treatment.

bioRxiv · Jan 20, 2022 · PreprintCancer Biology